Bernstein downgrades Alnylam to Market Perform on TRITON-CM trial design
FROM THE WIRE · SEEKINGALPHA.COM
[Wall Street sign in Lower Manhattan, NYC] georgeclerk Bernstein on Friday downgraded Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) to Market Perform from Outperform, citing concerns over the design of its TRITON-CM Phase 3 trial for its next-generation…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe downgrade adds pressure on a stock already down over 25% after results.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Bernstein cut its rating from Outperform to Market Perform.
- 02The analyst disputes the design of the Phase 3 TRITON-CM trial for nucresiran.
- 03Alnylam reiterated its 2026 revenue outlook below FactSet consensus.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets